Enzalutamide and Metformin Combination Therapy to Overcome Autophagy Resistance in Castration Resistant Prostate Cancer

Trial Profile

Enzalutamide and Metformin Combination Therapy to Overcome Autophagy Resistance in Castration Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Enzalutamide (Primary) ; Metformin (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2018.
    • 10 Feb 2018 Results assessing enzalutamide and metformin combination therapy to overcome autophagy resistance in castration resistant prostate cancer, were presented at the 2018 Genitourinary Cancers Symposium.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top